Yazar "Akarca, U. S." seçeneğine göre listele
Listeleniyor 1 - 20 / 27
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Adefovir treatment of entecavir resistance in patients with lamivudine-refractory chronic hepatitis B(Elsevier Science Bv, 2008) Yurdaydin, C.; Idilman, R.; Cevik, E.; Akarca, U. S.; Kaymakoglu, S.; Bozdayi, A. M.Öğe Analogs and fibrosis regression in hepatitis B(Masson Editeur, 2010) Akarca, U. S.Öğe Comparative antiviral efficacy with higher ALT normalization of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in HBeAg-negative, genotype D chronic hepatitis B(Elsevier Science Inc, 2017) Ricco, G.; Buti, M.; Omata, M.; Kim, Y. J.; Coco, B.; Samuel, D.; Flaherty, J. F.; Lin, L.; Gaggar, A.; Ceausu, E.; Akarca, U. S.; Tong, M. J.; Chan, H. L.; Brunetto, M. R.Öğe CONSOLIDATION THERAPY WITH ENTECAVIR CAN PREVENT POST-TREATMENT HBsAg REBOUND IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALPHA(Elsevier Science Bv, 2015) Brouwer, W. P.; Sonneveld, M. J.; Xie, Q.; Zhang, N.; Zeuzem, S.; Tabak, F.; Zhang, Q.; Simon, K.; Akarca, U. S.; Streinu-Cercel, A.; Hansen, B.; Janssen, H. L.Öğe CONSOLIDATION THERAPY WITH ENTECAVIR CAN PREVENT POST-TREATMENT HBsAg REBOUND IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALPHA(Elsevier Science Bv, 2015) Brouwer, W. P.; Sonneveld, M. J.; Xie, Q.; Zhang, N.; Zeuzem, S.; Tabak, F.; Zhang, Q.; Simon, K.; Akarca, U. S.; Streinu-Cercel, A.; Hansen, B.; Janssen, H. L.Öğe CONSOLIDATION THERAPY WITH ENTECAVIR CAN PREVENT POST-TREATMENT HBsAg REBOUND IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALPHA(Elsevier Science Bv, 2015) Brouwer, W. P.; Sonneveld, M. J.; Xie, Q.; Zhang, N.; Zeuzem, S.; Tabak, F.; Zhang, Q.; Simon, K.; Akarca, U. S.; Streinu-Cercel, A.; Hansen, B.; Janssen, H. L.Öğe Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (study ETV-027)(Elsevier Science Bv, 2006) Shouval, D.; Akarca, U. S.; Hatzis, G.; Kitis, G.; Lai, C. L.; Cheinquer, H.; Chang, T. T.; Zink, R.; Zhu, J.; Brett-Smith, H.Öğe Correlation of immunohistochemistry on liver biopsy and serum HBVDNA levels(Elsevier Science Bv, 2008) Yilmaz, F.; Nart, D.; Vardar, R.; Gunsar, F.; Ersoz, G.; Karasu, Z.; Sertoz, R.; Erensoy, S.; Ilter, T.; Batur, Y.; Akarca, U. S.Öğe DELTA VIRUS COINFECTION DOES NOT INCREASE, BUT HCV COINFECTION INCREASE THE HBSAG LOSS, IN CHRONIC HBV INFECTION(Elsevier Science Bv, 2011) Yapali, S.; Bayrakci, B.; Gunsar, F.; Ersoz, G.; Karasu, Z.; Akarca, U. S.Öğe Early reduction of serum HBsAg Levels in HBeAg-negative chronic hepatitis B patients achieving sustained virological response after peginterferon alpha-2a +/- ribavirin treatment(Lippincott Williams & Wilkins, 2009) Rijckborst, V.; ter Borg, M. J.; Akarca, U. S.; Grima, P.; Flisiak, R.; Zouboulis, I. Vafiadis; Tripi, S.; van Doornum, G. J. J.; Verhey, E.; van Vuuren, A. J.; Hansen, B. E.; Janssen, H. L. A.Öğe Effects of insulin sensitizing agents in nonalcoholic fatty liver disease(Elsevier Science Bv, 2007) Omer, Z.; Cetinkalp, S.; Akyildiz, M.; Barbet, F. Yilmaz; Yilmaz, C.; Batur, Y.; Akarca, U. S.Öğe Entecavir (ETV) treatment through 96 weeks results in virologic and biochemical improvement in HBeAg(-) chronic hepatitis B patients (study ETV-027)(Elsevier Science Bv, 2006) Manns, M.; Shouval, D.; Akarca, U. S.; Hatzis, G.; Kitis, G.; Zink, R.; Zhu, J.; Brett-Smith, H.Öğe ENTECAVIR AND TENOFOVIR MONOTHERAPY IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER TURKISH STUDY IN CLINICAL PRACTICE(Elsevier Science Bv, 2014) Idilman, R.; Keskin, O.; Gunsar, F.; Koruk, M.; Meral, C. E.; Tuzun, A.; Gulsen, M.; Elhan, A. H.; Akarca, U. S.; Yurdaydin, C.Öğe Evaluation of patients with positive anti-mitochondiral antibody and normal alkaline phosphatase levels for primary biliary cholangitis(Univ Catholique Louvain-Ucl, 2024) Ellez, H. I.; Danis, N.; Akarca, U. S.Primary Biliary Cholangitis (PBC) is a chronic cholestatic liver disease typically diagnosed by elevated cholestatic liver enzymes and a positive anti-mitochondrial antibody (AMA) test. The clinical importance of AMA positivity in patients with normal cholestatic liver enzymes is unclear. The aim of this study was to determine the relationship between PBC and AMA positivity detected in individuals with normal cholestatic enzyme levels. The files of patients with AMA and/or AMA-M2 positivity between 2009 and 2018 and whose alkaline phosphatase (ALP) levels were below upper limit of normal (ULN) at initial admission were retrospectively analyzed. The ALP levels were normal in all patients. All patients had AMA positivity demonstrated by indirect immunofluorescence (IIF) or AMA-M2 positivity demonstrated by ELISA. A total of 16 patients underwent liver biopsy and seven (43.75%) showed changes consistent with those with PBC. A total of 12 patients were diagnosed with PBC and were treated and followed up with this diagnosis. People with AMA positivity and normal cholestasis enzyme levels are closely associated with PBC. Some of these patients were diagnosed with PBC as a result of biopsy and some were diagnosed by clinical and laboratory findings during follow-up.. The patients with an AMA titration of 1/20 were not associated with PBC. In our study, results similar to the studies confirmed by biopsies were obtained. In this regard, there is a need for prospective and retrospective studies with longer follow-up periods. (Acta gastroenterol. belg., 2024, , 87, 282-286).Öğe FIBROSIS SHOULD BE INCLUDED INTO THE NONALCOHOLIC STEATOHEPATITIS SCORING SYSTEM FOR BEING MORE PROGNOSTICATIVE(Elsevier Science Bv, 2009) Gunsar, F.; Yilmaz, F.; Unal, N. G.; Bayrakci, B.; Karasu, Z.; Nart, D.; Ersoz, G.; Akarca, U. S.Öğe Lamivudine monoprophylaxis prevents HBV infection in recipients undergoing live donor liver transplantation because of non-HBV related diseases, having their grafts from core-antibody positive donors(Elsevier Science Bv, 2007) Karasu, Z.; Akyildiz, M.; Ozacar, T.; Yilmaz, F.; Akarca, U. S.; Ersoz, G.; Gunsar, F.; Aydin, U.; Kilic, M.; Ilter, T.Öğe Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naive chronic hepatitis B patients in the real-world setting(Wiley-Blackwell, 2015) Idilman, R.; Gunsar, F.; Koruk, M.; Keskin, O.; Meral, C. E.; Gulsen, M.; Elhan, A. H.; Akarca, U. S.; Yurdaydin, C.The aim of this study was to determine the long-term efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) on the natural course of disease in chronic hepatitis B patients (CHB) with/without cirrhosis in clinical practice. A total of 355 treatment-naive CHB patients were enrolled into the study. The primary outcome measure was viral suppression as defined by serum HBV DNA level <20IU/mL. A secondary outcome measure was to determine the development of Hepatocellular carcinoma (HCC). Virological and biochemical responses were similar between the two treatment groups over time. The presence of cirrhosis and hepatitis B e antigen (HBeAg) positivity did not appear to impact viral suppression. The cumulative probability of HBeAg loss was 41% at 4years of therapy. Hepatitis B surface antigen (HBsAg) loss occurred in four patients. Model for End-Stage Liver Disease score was significantly improved from baseline to week 48 and 96 under antiviral therapy (P=0.013, P=0.01). HCC was diagnosed in 17 patients (4.8%). The cumulative probability of the development of HCC was 3.3% at 1year and 7.3% at 4years of therapy. The development of HCC was independently associated with older age (P=0.031) and the presence of cirrhosis (P=0.004). Serum creatinine levels and creatinine clearance remained stable over time. ETV and TDF effectively maintained virological and biochemical responses in long-term follow-up of CHB patients with/without cirrhosis. HCC may still develop, although at a lower rate, and is more likely to develop in patients with cirrhosis, especially in older patients.Öğe Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naive chronic hepatitis B patients in the real-world setting(Wiley-Blackwell, 2015) Idilman, R.; Gunsar, F.; Koruk, M.; Keskin, O.; Meral, C. E.; Gulsen, M.; Elhan, A. H.; Akarca, U. S.; Yurdaydin, C.The aim of this study was to determine the long-term efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) on the natural course of disease in chronic hepatitis B patients (CHB) with/without cirrhosis in clinical practice. A total of 355 treatment-naive CHB patients were enrolled into the study. The primary outcome measure was viral suppression as defined by serum HBV DNA level <20IU/mL. A secondary outcome measure was to determine the development of Hepatocellular carcinoma (HCC). Virological and biochemical responses were similar between the two treatment groups over time. The presence of cirrhosis and hepatitis B e antigen (HBeAg) positivity did not appear to impact viral suppression. The cumulative probability of HBeAg loss was 41% at 4years of therapy. Hepatitis B surface antigen (HBsAg) loss occurred in four patients. Model for End-Stage Liver Disease score was significantly improved from baseline to week 48 and 96 under antiviral therapy (P=0.013, P=0.01). HCC was diagnosed in 17 patients (4.8%). The cumulative probability of the development of HCC was 3.3% at 1year and 7.3% at 4years of therapy. The development of HCC was independently associated with older age (P=0.031) and the presence of cirrhosis (P=0.004). Serum creatinine levels and creatinine clearance remained stable over time. ETV and TDF effectively maintained virological and biochemical responses in long-term follow-up of CHB patients with/without cirrhosis. HCC may still develop, although at a lower rate, and is more likely to develop in patients with cirrhosis, especially in older patients.Öğe Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naive chronic hepatitis B patients in the real-world setting(Wiley-Blackwell, 2015) Idilman, R.; Gunsar, F.; Koruk, M.; Keskin, O.; Meral, C. E.; Gulsen, M.; Elhan, A. H.; Akarca, U. S.; Yurdaydin, C.The aim of this study was to determine the long-term efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) on the natural course of disease in chronic hepatitis B patients (CHB) with/without cirrhosis in clinical practice. A total of 355 treatment-naive CHB patients were enrolled into the study. The primary outcome measure was viral suppression as defined by serum HBV DNA level <20IU/mL. A secondary outcome measure was to determine the development of Hepatocellular carcinoma (HCC). Virological and biochemical responses were similar between the two treatment groups over time. The presence of cirrhosis and hepatitis B e antigen (HBeAg) positivity did not appear to impact viral suppression. The cumulative probability of HBeAg loss was 41% at 4years of therapy. Hepatitis B surface antigen (HBsAg) loss occurred in four patients. Model for End-Stage Liver Disease score was significantly improved from baseline to week 48 and 96 under antiviral therapy (P=0.013, P=0.01). HCC was diagnosed in 17 patients (4.8%). The cumulative probability of the development of HCC was 3.3% at 1year and 7.3% at 4years of therapy. The development of HCC was independently associated with older age (P=0.031) and the presence of cirrhosis (P=0.004). Serum creatinine levels and creatinine clearance remained stable over time. ETV and TDF effectively maintained virological and biochemical responses in long-term follow-up of CHB patients with/without cirrhosis. HCC may still develop, although at a lower rate, and is more likely to develop in patients with cirrhosis, especially in older patients.Öğe Loss of intrahepatic HBsAg expression predicts sustained response to peginterferon and is reflected by pronounced serum HBsAg decline(Wiley, 2014) Arends, P.; Rijckborst, V.; Zondervan, P. E.; Buster, E.; Cakaloglu, Y.; Ferenci, P.; Tabak, F.; Akarca, U. S.; Simon, K.; Sonneveld, M. J.; Hansen, B. E.; Janssen, H. L. A.There is a lack of knowledge regarding the effect of peginterferon (PEG-IFN) on the expression of intrahepatic hepatitis B core and surface antigen (HBcAg and HBsAg) in chronic hepatitis B (CHB) and its relation with response to therapy. Fifty-two HBeAg-positive and 67 HBeAg-negative CHB patients with paired liver biopsies taken at baseline and after 1year of PEG-IFN therapy were studied. After PEG-IFN therapy, HBeAg-negative patients showed a significant reduction in both intrahepatic HBcAg (P=0.04) and HBsAg expression (P<0.001). In contrast, a reduction in intrahepatic HBcAg expression was not observed in HBeAg-positive patients, while a trend in reduction of intrahepatic HBsAg staining was found (P=0.09). Post-treatment, 7 (13%) HBeAg-positive and 9 (14%) HBeAg-negative patients had no expression of intrahepatic HBsAg. Patients without any intrahepatic HBsAg expression post-treatment were more likely to achieve a combined response (HBeAg loss with hepatitis B virus (HBV) DNA <2000IU/mL for HBeAg -positive and HBV DNA <2000IU/mL and normal alanine aminotransferase for HBeAg-negative CHB): 71% vs 5% for HBeAg-positive (P<0.001) and 60% vs 16% for HBeAg-negative patients (P=0.004), respectively. Moreover, a more profound decline of serum HBsAg was observed in patients with absence of intrahepatic HBsAg staining (3.1 vs 0.4logIU/mL, P<0.001 and 1.7 vs 0.4logIU/mL, P=0.005 for HBeAg-positive and HBeAg-negative CHB, respectively). In conclusion, PEG-IFN reduces expression of intrahepatic HBsAg. Loss of HBsAg as assessed by immunohistochemistry from the liver predicts a sustained response and is reflected in a pronounced serum HBsAg decline.
